Boehringer’s Smith Discusses The Challenges Of Diabetes At ADA
This article was originally published in The Pink Sheet Daily
Executive Summary
Relatively new to the diabetes space, Boehringer Ingelheim is trying to rapidly distinguish itself in a crowded field with four products each addressing a different patient need.
You may also be interested in...
Janssen Files Once-Daily Proteasome Inhibitor; Other New Drug News, In Brief
Boehringer Ingelheim submits type 2 diabetes therapy empagliflozin; Pozen seeks a partner to help it commercialize its aspirin/PPI combo following its NDA submission; Eisai gets FDA approval for pediatric use of acid reflux drug Aciphex; Merck announces FDA’s acceptance of its oral grass pollen allergy immunotherapy BLA; the EMA accepts Shionogi’s menopause drug Osphena for review, and IntelGenx submits an NDA for an oral film version of Maxalt-MLT.
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.
Lilly/BI Report Success For Oral Diabetes Drug, Adjust Alliance
Eli Lilly and Boehringer Ingelheim announced positive top-line data for a quartet of pivotal trials of their SGLT-2 candidate empagliflozin, while Lilly now will be going it alone on LY2605541, a long-acting insulin.